CA1161754A - Surface active material, method for producing the same, and pharmaceutical composition for hyaline- membrane disease containing said material - Google Patents

Surface active material, method for producing the same, and pharmaceutical composition for hyaline- membrane disease containing said material

Info

Publication number
CA1161754A
CA1161754A CA000353105A CA353105A CA1161754A CA 1161754 A CA1161754 A CA 1161754A CA 000353105 A CA000353105 A CA 000353105A CA 353105 A CA353105 A CA 353105A CA 1161754 A CA1161754 A CA 1161754A
Authority
CA
Canada
Prior art keywords
content
suspension
active material
phospholipid
rpm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000353105A
Other languages
English (en)
French (fr)
Inventor
Fujiwara Tetsuro
Tanaka Yuji
Takei Tsunetomo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Tokyo Tanabe Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=13367224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1161754(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tokyo Tanabe Co Ltd filed Critical Tokyo Tanabe Co Ltd
Application granted granted Critical
Publication of CA1161754A publication Critical patent/CA1161754A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Steroid Compounds (AREA)
CA000353105A 1979-06-02 1980-05-30 Surface active material, method for producing the same, and pharmaceutical composition for hyaline- membrane disease containing said material Expired CA1161754A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6821179A JPS55160721A (en) 1979-06-02 1979-06-02 Pulmonary surfactant ta-546, its preparation, and remedy for pulmonary hyaline membrane syndrome comprising it as active constituent
JP68,211/1979 1979-06-02

Publications (1)

Publication Number Publication Date
CA1161754A true CA1161754A (en) 1984-02-07

Family

ID=13367224

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000353105A Expired CA1161754A (en) 1979-06-02 1980-05-30 Surface active material, method for producing the same, and pharmaceutical composition for hyaline- membrane disease containing said material

Country Status (8)

Country Link
US (1) US4338301A (enExample)
JP (1) JPS55160721A (enExample)
AU (1) AU520543B2 (enExample)
CA (1) CA1161754A (enExample)
DE (1) DE3021006C2 (enExample)
FR (1) FR2457872A1 (enExample)
GB (1) GB2050832B (enExample)
MX (1) MX9203482A (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5795920A (en) * 1980-12-04 1982-06-15 Teijin Ltd Remedy for respiratory disease
DE3228629A1 (de) * 1982-07-31 1984-02-02 Reifenrath, Rainer Richard Otto, Dr., 3104 Unterlüß Pharmazeutisches erzeugnis zur behandlung der atemwege und verfahren zu seiner herstellung
DE3229179C2 (de) * 1982-08-05 1986-04-17 A. Nattermann & Cie GmbH, 5000 Köln Lungensurfactant
JPS59164724A (ja) * 1983-03-10 1984-09-17 Tokyo Tanabe Co Ltd サ−フアクタント及びそれを含有する呼吸窮迫症候群治療剤
DD225841C2 (de) * 1983-12-08 1986-04-16 Dresden Arzneimittel Verfahren zur herstellung eines mittels zur behandlung von erkrankungen, die mit veraenderungen des pulmonalen surfactant-systems einhergehen
CS938384A1 (en) * 1983-12-08 1990-08-14 Lachmann Burkhardt Pharmaceutical agent for breathlesness therapy and method of its production
FR2559669B1 (fr) * 1984-02-20 1986-05-09 Nabavi Seyfeddine Lipoproteine haute densite cholesterol synthetique
IL71051A (en) * 1984-02-23 1988-02-29 Yeda Res & Dev Compositions containing active lipids for the treatment of cystic fibrosis
US5013720A (en) * 1986-05-06 1991-05-07 Abbott Laboratories SAP-6-Val proteins and methods
JPH01501282A (ja) * 1986-12-08 1989-05-11 ホイツトセツト，ジエフリー　エイ． 肺胞疎水性界面活性物質関連タンパク質
IT1203873B (it) * 1987-04-08 1989-02-23 Chiesi Farma Spa Composizioni farmaceutiche che lo surfattante polmonare naturale, contengono. metodo di preparazione e
US4861756A (en) * 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
AU3073789A (en) * 1988-03-31 1989-10-05 Abbott Laboratories Drug delivery using pulmonary surfactant to facilitate absorption
DE3921954A1 (de) * 1989-07-04 1991-01-17 Thomae Gmbh Dr K Niedrig-viskose, hochkonzentrierte surfactant-suspension
CO5021218A1 (es) * 1994-12-29 2001-03-27 Ct Nac De Sanidad Agropecuaria Surfactante pulmonar natural porcino
US6129934A (en) * 1995-06-07 2000-10-10 Ony, Inc. Modification of animal lung surfactant for treating respiratory disease due to lung surfactant deficiency or dysfunction
US6172203B1 (en) * 1996-02-07 2001-01-09 Alfredo Adolfo Hager Method for extracting and purifying pulmonary surfactant
EP0904295B1 (en) * 1996-05-15 2005-08-10 ALTANA Pharma AG Process for separating and analyzing hydrophobic proteins using thin layer chromatography
US6855342B2 (en) * 2000-06-30 2005-02-15 Medicis Pharmaceutical Corporation Compositions and methods for high sorption of skin materials and delivery of sulfur
US6514489B1 (en) 2000-06-30 2003-02-04 Medicis Pharmaceutical Corp. Sulfur containing dermatological compositions and methods for reducing malodors in dermatological compositions
US20050025817A1 (en) * 2003-07-03 2005-02-03 Bhatia Kuljit S. Delivery system for topical medications
US7479289B2 (en) * 2004-07-02 2009-01-20 Medicis Pharmaceutical Corporation Stable cleanser compositions containing sulfur
US7582312B2 (en) * 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US7464012B2 (en) * 2004-12-10 2008-12-09 L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude Simplified process simulator
GB0426010D0 (en) * 2004-11-26 2004-12-29 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials
US11219843B2 (en) * 2019-07-08 2022-01-11 Nik Paya Karen Pharmed Extraction of animal-derived pulmonary surfactants

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594476A (en) * 1969-05-12 1971-07-20 Massachusetts Inst Technology Submicron aqueous aerosols containing lecithin

Also Published As

Publication number Publication date
AU5867880A (en) 1981-12-10
FR2457872A1 (fr) 1980-12-26
FR2457872B1 (enExample) 1984-09-21
DE3021006C2 (de) 1983-03-17
MX9203482A (es) 1992-08-01
JPS55160721A (en) 1980-12-13
GB2050832A (en) 1981-01-14
DE3021006A1 (de) 1981-01-08
GB2050832B (en) 1983-08-03
US4338301A (en) 1982-07-06
AU520543B2 (en) 1982-02-04
JPS619925B2 (enExample) 1986-03-27

Similar Documents

Publication Publication Date Title
CA1161754A (en) Surface active material, method for producing the same, and pharmaceutical composition for hyaline- membrane disease containing said material
CA1208129A (en) Surfactant and pharmaceutical compositions containing same
Sun et al. Surfactant inhibition in experimental meconium aspiration
Anderstam et al. Middle-sized molecule fractions isolated from uremic ultrafiltrate and normal urine inhibit ingestive behavior in the rat.
Adams et al. Effects of tracheal instillation of natural surfactant in premature lambs. I. Clinical and autopsy findings
FI92905B (fi) Menetelmä eläinperäisen keuhkojen pinta-aktiivisen aineen valmistamiseksi
US4397839A (en) Surface active material and process for preparing same
Adams et al. Surface properties and lipids from lungs of infants with hyaline membrane disease
Hallman et al. Role of myoinositol in regulation of surfactant phospholipids in the newborn
Kobayashi et al. The critical concentration of surfactant in fetal lung liquid at birth
EP0145005B1 (de) Lungen-Surfactant, Verfahren zu seiner Herstellung und seine pharmazeutische Verwendung
Zwaal et al. The lipid bilayer concept of cell membranes
DE69928279T2 (de) Lungensurfactant zubereitungen enthaltendes behandlungset
DE69519332T2 (de) Liposomen mit eingekapseltem Hämoglobin
Agroyannis et al. Alterations in echinocyte transformation and erythrocyte sedimentation rate during hemodialysis
US20240366682A1 (en) Process for the preparation of a pulmonary surfactant
DD225841C2 (de) Verfahren zur herstellung eines mittels zur behandlung von erkrankungen, die mit veraenderungen des pulmonalen surfactant-systems einhergehen
RU2066197C1 (ru) Способ получения легочного сурфактанта
DD225840A3 (de) Verfahren zur herstellung eines mittels zur behandlung von erkrankungen, die mit veraenderungen im pulmonalen surfactant-system einhergehen
KR960013436B1 (ko) 천연 폐 계면활성제, 그의 제조방법 및 이것을 함유하는 제약 조성물
Dezfouli et al. The Factors Effect on Natural Lung Surfactant Content for the Treatment of Respiratory Distress Syndrome
RU2066198C1 (ru) Способ получения легочного сурфактанта
JPS6361000A (ja) リポ蛋白質及びその製造法
Spragg Abnormalities of the Lung Surfactant System in Acute Lung Injury
DD231189A3 (de) Mittel zur behandlung von erkrankungen, die mit veraenderungen im lungensurfactant verbunden sind, sowie verfahren zur herstellung desselben

Legal Events

Date Code Title Description
MKEX Expiry